A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
Open Access
- 25 May 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (34) , 56921-56931
Abstract
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experienceKeywords
This publication has 30 references indexed in Scilit:
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trialThe Lancet Oncology, 2017
- Novel approaches to target HER2-positive breast cancer: trastuzumab emtansineCancer Management and Research, 2016
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and CapecitabineJournal of Clinical Oncology, 2012
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 StudyJournal of Clinical Oncology, 2012
- p95HER2 and Breast CancerCancer Research, 2011
- Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 ReceptorClinical Cancer Research, 2010
- Trastuzumab — Mechanism of Action and Use in Clinical PracticeNew England Journal of Medicine, 2007
- Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.2001
- Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStatistics in Medicine, 1998